Cellectis S.a. logo

Cellectis S.a. (CLLS) live share price

Cellectis S.a. share price in USD $2.02 & INR ₹171.08

$2.02

▲

-0.08

(-3.81%)

View live Cellectis S.a. share price in Dollar and Rupees. Guide to invest in Cellectis S.a. from India. Also see the sentimental analysis on Indian investors investing in Cellectis S.a.. Get details on the Indian mutual funds that are investing in Cellectis S.a.. Get Analyst recommendations and forecasts along with all the Cellectis S.a.'s financials.

Cellectis S.a. share price movements

  • $2.00
    $2.08

    Day's Volatility :3.72%

  • $1.70
    $3.77

    52 Weeks Volatility :54.95%

Cellectis S.a. Returns

PeriodCellectis S.a.Sector (Health Care)Index (Russel 2000)
3 Months
-7.08%
-6.2%
0.0%
6 Months
-18.29%
2.6%
0.0%
1 Year
-26.83%
11.8%
0.0%
3 Years
-73.91%
13.3%
-19.8%

Cellectis S.a. Key Statistics

in dollars & INR

Market Capitalization
$213.2M
Revenue TTM
$36.0M
EBITDA
$-67.2M
Earnings Per Share (EPS)
$-1.16
Profit Margin
-234.39%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-82.2%

How to invest in Cellectis S.a. from India?

It is very easy for Indian residents to invest directly in Cellectis S.a. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cellectis S.a. stock in both rupees (INR) and dollars (USD). Search for Cellectis S.a. or CLLS on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cellectis S.a. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cellectis S.a. shares which would translate to 0.419 fractional shares of Cellectis S.a. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Cellectis S.a.

50%

Period: Sep 3, 2024 to Dec 2, 2024. Change in 30 Days versus previous period

Search volume for Cellectis S.a. on INDmoney from India has grown in the last 30 days as on Dec 3, 2024. 50% more investors are searching Cellectis S.a. in the last 30 days versus the previous period.

Global Institutional Holdings in Cellectis S.a.

  • Long Focus Capital Management, LLC

    4.61%

  • Capital Research & Mgmt Co - Division 3

    1.85%

  • UBS Asset Mgmt Americas Inc

    1.44%

  • Baillie Gifford & Co Limited.

    0.69%

  • Principal Financial Group Inc

    0.41%

  • Macquarie Group Ltd

    0.23%

Analyst Recommendation on Cellectis S.a.

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Cellectis S.a.(by analysts ranked 0 to 5 stars)

Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Cellectis S.a.

What analysts predicted

Upside of 221.78%

Current:

$2.02

Target:

$6.50

Insights on Cellectis S.a.

  • Increasing Revenue

    Revenue is up for the last 7 quarters, 139.0K → 16.2M (in $), with an average increase of 40.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -25.27M → -23.05M (in $), with an average increase of 9.6% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 47.6% return, outperforming this stock by 78.5%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.4% return, outperforming this stock by 114.0%

Cellectis S.a. Financials in INR & Dollars

FY18Y/Y Change
Revenue
$12.7M
↓ 49.46%
Net Income
$-78.7M
↓ 20.81%
Net Profit Margin
-618.12%
↓ 223.61%
FY19Y/Y Change
Revenue
$15.2M
↑ 19.32%
Net Income
$-90.7M
↑ 15.24%
Net Profit Margin
-597.01%
↑ 21.11%
FY20Y/Y Change
Revenue
$73.9M
↑ 386.83%
Net Income
$-72.6M
↓ 19.98%
Net Profit Margin
-98.14%
↑ 498.87%
FY21Y/Y Change
Revenue
$73.9M
↑ 0.0%
Net Income
$-86.3M
↑ 18.89%
Net Profit Margin
-116.68%
↓ 18.54%
FY22Y/Y Change
Revenue
$19.2M
↓ 74.08%
Net Income
$-98.7M
↑ 14.38%
Net Profit Margin
-514.78%
↓ 398.1%
FY23Y/Y Change
Revenue
$755.0K
↓ 96.06%
Net Income
$-101.1M
↑ 2.4%
Net Profit Margin
-13.4K%
↓ 12870.52%
Q2 FY23Q/Q Change
Revenue
$155.0K
↑ 11.51%
Net Income
$-17.5M
↓ 41.87%
Net Profit Margin
-11.3K%
↑ 10357.26%
Q3 FY23Q/Q Change
Revenue
$283.0K
↑ 82.58%
Net Income
$-42.9M
↑ 145.18%
Net Profit Margin
-15.1K%
↓ 3866.87%
Q4 FY23Q/Q Change
Revenue
$283.0K
↑ 0.0%
Net Income
$-42.9M
↑ 0.0%
Net Profit Margin
-15.1K%
↑ 0.0%
Q1 FY24Q/Q Change
Revenue
$4.5M
↑ 1500.0%
Net Income
$5.6M
↓ 113.17%
Net Profit Margin
124.62%
↑ 15270.2%
Q2 FY24Q/Q Change
Revenue
$8.1M
↑ 78.03%
Net Income
$-25.3M
↓ 547.81%
Net Profit Margin
-313.48%
↓ 438.1%
Q3 FY24Q/Q Change
Revenue
$16.2M
↑ 100.97%
Net Income
$-23.1M
↓ 8.76%
Net Profit Margin
-142.32%
↑ 171.16%
FY18Y/Y Change
Total Assets
$500.8M
↑ 50.46%
Total Liabilities
$50.6M
↑ 7.64%
FY19Y/Y Change
Total Assets
$467.5M
↓ 6.66%
Total Liabilities
$112.0M
↑ 121.48%
FY20Y/Y Change
Total Assets
$469.5M
↑ 0.43%
Total Liabilities
$160.6M
↑ 43.42%
FY21Y/Y Change
Total Assets
$382.1M
↓ 18.62%
Total Liabilities
$145.6M
↓ 9.35%
FY22Y/Y Change
Total Assets
$261.2M
↓ 31.63%
Total Liabilities
$135.3M
↓ 7.09%
FY23Y/Y Change
Total Assets
$334.3M
↑ 27.97%
Total Liabilities
$249.6M
↑ 84.49%
Q2 FY23Q/Q Change
Total Assets
$209.7M
↓ 16.59%
Total Liabilities
$133.6M
↑ 2.03%
Q3 FY23Q/Q Change
Total Assets
$334.3M
↑ 59.4%
Total Liabilities
$249.6M
↑ 86.84%
Q4 FY23Q/Q Change
Total Assets
$334.3M
↑ 0.0%
Total Liabilities
$249.6M
↑ 0.0%
Q1 FY24Q/Q Change
Total Assets
$354.5M
↑ 6.04%
Total Liabilities
$263.9M
↑ 5.74%
Q2 FY24Q/Q Change
Total Assets
$407.1M
↑ 14.86%
Total Liabilities
$258.5M
↓ 2.03%
Q3 FY24Q/Q Change
Total Assets
$395.9M
↓ 2.77%
Total Liabilities
$266.5M
↑ 3.06%
FY18Y/Y Change
Operating Cash Flow
$-68.1M
↑ 30.21%
Investing Cash Flow
$35.6M
↑ 1896.8%
Financing Cash Flow
$236.5M
↑ 473.1%
FY19Y/Y Change
Operating Cash Flow
$-69.1M
↑ 1.47%
Investing Cash Flow
$-35.9M
↓ 200.7%
Financing Cash Flow
$-3.9M
↓ 101.63%
FY20Y/Y Change
Operating Cash Flow
$-80.3M
↑ 16.08%
Investing Cash Flow
$-54.3M
↑ 51.49%
Financing Cash Flow
$27.3M
↓ 807.46%
FY21Y/Y Change
Operating Cash Flow
$-104.6M
↑ 30.28%
Investing Cash Flow
$7.3M
↓ 113.39%
Financing Cash Flow
$47.5M
↑ 73.94%
FY22Y/Y Change
Operating Cash Flow
$-87.4M
↓ 16.37%
Investing Cash Flow
$-2.8M
↓ 137.93%
Financing Cash Flow
$1.1M
↓ 97.59%
Q2 FY23Q/Q Change
Operating Cash Flow
$-17.1M
↓ 39.65%
Investing Cash Flow
$-1.8M
↑ 0.0%
Financing Cash Flow
$1.7M
↓ 91.47%

Cellectis S.a. Technicals Summary

Sell

Neutral

Buy

Cellectis S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Cellectis S.a. Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cellectis S.a.
Cellectis S.a.
19.32%
-18.29%
-26.83%
-73.91%
-85.58%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.49%
-24.47%
-8.88%
20.04%
103.68%
Biontech Se
Biontech Se
8.64%
19.01%
18.5%
-57.69%
426.41%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-6.25%
68.98%
46.39%
42.98%
103.71%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.99%
-1.44%
33.51%
128.29%
109.86%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cellectis S.a.
Cellectis S.a.
NA
NA
0.0
-0.7
-0.82
-0.16
NA
1.29
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.55
18.66
1.12
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.06
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cellectis S.a.
Cellectis S.a.
Buy
$210.2M
-85.58%
NA
-234.39%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.0B
103.68%
18.55
33.61%
Biontech Se
Biontech Se
Buy
$28.9B
426.41%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.7B
103.71%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
109.86%
32.84
-4.51%

About Cellectis S.a.

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Organization
Cellectis S.a.
Employees
216
CEO
Dr. Andre Choulika Ph.D.
Industry
Health Technology

Important FAQs about investing in Cellectis S.a. from India :

What is Cellectis S.a. share price today?

Cellectis S.a. (CLLS) share price today is $2.02.

Can Indians buy Cellectis S.a. shares?

Yes, Indians can invest in the Cellectis S.a. (CLLS) from India.

With INDmoney, you can buy Cellectis S.a. at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Cellectis S.a. at zero transaction cost.

How can I buy Cellectis S.a. shares from India?

It is very easy to buy Cellectis S.a. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cellectis S.a. be purchased?

Yes, you can buy fractional shares of Cellectis S.a. with INDmoney app.

What are the documents required to start investing in Cellectis S.a. stocks?

To start investing in Cellectis S.a., You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Cellectis S.a.

Today’s highest price of Cellectis S.a. (CLLS) is $2.08.

Today’s lowest price of Cellectis S.a. (CLLS) is $2.00.

What is today's market capitalisation of Cellectis S.a.

Today's market capitalisation of Cellectis S.a. CLLS is 210.2M

What is the 52 Week High and Low Range of Cellectis S.a.

  • 52 Week High

    $3.77

  • 52 Week Low

    $1.70

How much percentage Cellectis S.a. is down from its 52 Week High?

Cellectis S.a. (CLLS) share price is $2.02. It is down by 99% from its 52 Week High price of $3.77.

How much percentage Cellectis S.a. is up from its 52 Week low?

Cellectis S.a. (CLLS) share price is $2.02. It is up by 1% from its 52 Week Low price of $1.70.

What are the historical returns of Cellectis S.a.?

  • 1 Month Returns

    19.32%

  • 3 Months Returns

    -18.29%

  • 1 Year Returns

    -26.83%

  • 5 Years Returns

    -85.58%

Who is the Chief Executive Officer (CEO) of Cellectis S.a.

Dr. Andre Choulika Ph.D. is the current Chief Executive Officer (CEO) of Cellectis S.a..